Jared Kaltwasser

The report showed the protective benefits varied somewhat by cardiovascular disease subtype.

A new analysis from a Massachusetts health system found in-hospital infections occurred at a higher rate when the Omicron variant was present compared to when wild-type SARS-CoV-2 was prevalent.

Patients with a history of infection who were also vaccinated had the strongest protection, the data showed.

Rather than developing vaccines for each new variant, some officials are pushing to follow the flu vaccine model, with annual vaccination.

Patients who took RBX2660 following antibiotic therapy had lower rates of recurrence and double the time to recurrence, compared to patients taking placebo.

The microbiota-based live therapeutic had a 68.3% success rate when administered following antibiotic treatment, versus a 55% success rate in a placebo group.

Most of the discussion around fecal microbiota transplantation has focused on bacterial communities, but new advances have shed more light on the role of the virome.

About 65% of patients with metronidazole-resistant recurrent C difficile infection benefitted from taking rifaximin.

In a mouse model, the product protected against C difficile without eliminating the antibiotic’s presence in the blood.

The technology platform could speed up the development of novel therapeutics to combat virulence.

In a small retrospective study, 7 of 11 patients experienced clinical improvement.

Nearly 8 in 10 patients with recurrent C. diff. Infection were successfully treated after up to 2 doses of the microbiota-based therapy.

In a case series of 18 patients, all but 3 were cured by single-donor fecal microbiota transplantation capsule therapy.

Finch Therapeutics said it is providing information to the Food and Drug Administration to explain its testing protocols.

The product is designed to eliminate some of the drawbacks of fecal microbiota transplantation.

A new report based on samples from Texas and Kenya found significant proportions of samples from patients with CDI had nonsusceptible isolates.

While Clostridioides difficile infection (CDI) risk appeared to drop, investigators said the overall risk of infection among patients was not changed in a statistically significant way.

A new orally delivered investigational therapy could help curb the costly and often recurring infection.

The results of the prospective study diverge from published retrospective studies.

The single-center study suggested shoes are a common transmission route, but also hinted at a diverse web of transmission involving humans, animals, and the environment.

In a study of more than 600 elderly Japanese, being overweight was a protective factor against Clostridioides difficile infection (CDI).

The investigational therapy, ibezapolstat, demonstrated promising results in early trials.

The results are likely specific to areas without hypervirulent strains of Clostridioides difficile, such as Australia.

Hospital-onset CDI rates dropped by 6% in the first quarter of the program, which launched in 2016.

A new report underscores what early data suggested about disparities in the risk of hospitalization and death from COVID-19.

Only about 60% of Americans have immunity, a number too low to protect the country through “herd immunity,” according to a new report.

The data, which reflects pre-pandemic routine vaccination levels, showed human papillomavirus vaccine rates increased among teens ages 13-17.

The model found patients whose physicians received artificial intelligence-based alerts also spend fewer days in the hospital.

In a head-to-head randomized controlled trial, 30% of outpatients who received convalescent plasma had disease progression, compared to 31.9% of patients who received placebo.

Public health guidance differed between countries in part because of a lack of relevant scientific evidence, resource limitations, and differing strategies, according to a new report.